The European regulatory environment strongly shapes market entry and brand strategy, as strict health-claim and labeling requirements increase compliance burdens but also help reinforce product quality and consumer trust
doi: 10.3389/fimmu.2024.1476859 Received 06 August 2024 Accepted 03 December 2024 Published 19 December 2024 Volume 15 - 2024 Edited by Carmelo Carmona-Rivera, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH), United States Reviewed by Jos Jiram Torres-Ruiz, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mexico Matteo Doglio, San Raffaele Hospital (IRCCS), Italy Lauren Robinson, Hospital for Special Surgery, United States Updates Copyright 2024 Zhou, Lei, Shi, Luo, Wu, Xu, Zhang, Liu, Wang, Zhou and He
Conclusions about retatrutide's full benefit profile should therefore remain cautious at this stage
When she published her first study, in 2012, on a GLP-1 drugs impact on the dopamine reward system, she had to spend two years going back and forth with skeptical reviewers